Floatz logo

ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166

HER2 Positive Gastric Cancer

Klus Pharma Inc.antibody_drug_conjugatePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

65 Active assets in the HER2 Positive Gastric Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Boehringer Ingelheim
Phase 3BB
Eloxatin
Shanghai Zhongshan Hospital
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB
TRASTUZUMAB
Boehringer Ingelheim
Phase 2BB

View all 50 →

Same molecule, other indications

ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
breast cancerDormant
B
Indicative ·
56 / 100
View asset →
tumor of salivary glandDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →